Pharmacological characteristics of a novel, recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP)

BACKGROUND: Recombinant factor VIIa (rFVIIa) is approved for use in controlling bleeding episodes in people with hemophilia who have developed inhibitors to replacement therapy. Due to its short half-life (t(½)), frequent injections are required, limiting its use as a prophylactic treatment. A novel...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Zollner, S, Schuermann, D, Raquet, E, Mueller-Cohrs, J, Weimer, T, Pragst, I, Dickneite, G, Schulte, S
Médium: Artigo
Jazyk:Inglês
Vydáno: Blackwell Publishing Ltd 2014
Témata:
Coagulation
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4166693/
https://ncbi.nlm.nih.gov/pubmed/24641308
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jth.12477
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky